Pre-made Lirilumab benchmark antibody ( Whole mAb, anti-KIRD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-316

Pre-Made Lirilumab biosimilar, Whole Mab: Anti-KIRD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-316-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg


Products Name (INN Index) Pre-Made Lirilumab biosimilar, Whole Mab: Anti-KIRD2 therapeutic antibody
INN Name Lirilumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesNovo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveChronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer
Conditions DiscontinuedAcute myeloid leukaemia;Hepatitis C;Haematological malignancies;Multiple myeloma;Lymphoma
Development TechMedarex UltiMAb Mouse